Zhou Y, Wang B, Qu J, et al. - In epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs), central nervous system (CNS) metastases are common complications, so researchers here assessed CNS metastasis development in 813 patients with EGFR-mutant advanced NSCLC without baseline CNS metastasis who are receiving first- and/or third-generation EGFR-TKIs. Among these patients, 562 received first-line gefitinib, 106, received first-line erlotinib, and and 32 received first-line osimertinib; 113 received second-line osimertinib. Outcomes revealed delayed development of symptomatic CNS metastasis in correlation with receiving osimertinib, but it did not prevent it. They indicated the independent value of L858R mutation as a risk factor of CNS metastasis. No association of the presence of baseline neuroimaging with prognosis was evident.